Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a Healthcare company (Biotechnology) with a market capitalization of $4.7B. The Maz Rating grades it against the other companies in its sector.
Edgewise Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $43.68, Edgewise Therapeutics, Inc. trades at 4.8x trailing earnings and 2.9x book value, with an EV/EBITDA of 4.0. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of 130.4%, return on invested capital of -11.6% and a free cash flow yield of -4.3%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 12.30. Over the past 52 weeks the share price ranged from $19.76 to $48.78, with a beta of 0.28.
Edgewise Therapeutics, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 9 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.